REVLIMID® (Lenalidomide)

June 29th, 2013

The FDA on June 5, 2013 approved REVLIMID® capsules for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included VELCADE® (Bortezomib). REVLIMID® is a product of Celgene Corporation.


XGEVA® (Denosumab)

June 29th, 2013

Advanced Melanoma – Bringing Bench Research to the Patient’s Bedside

June 14th, 2013

Lambrolizumab (MK-3475) is a humanized anti–PD-1 monoclonal antibody that has demonstrated significant benefit for those patients with advanced Malignant Melanoma regardless of their prior therapy with anti-CTLA 4 antibody, YERVOY® (Ipilimumab). The programmed death 1 (PD-1) receptor is an inhibitory receptor expressed on activated T-cells in the tumor micro environment. The anti–PD-1 antibody by blocking the PD-1 receptor essentially unleashes the immune system to fight off cancer cells. This information published in the NEJM in June 2013 and presented at the 2013 ASCO annual meeting gives an additional option for patients with advanced Malignant Melanoma.


MEKINIST® (Trametinib)

June 4th, 2013

TAFINLAR® (Dabrafenib)

June 4th, 2013

XOFIGO® (Radium Ra 223 dichloride)

June 4th, 2013

The FDA on May 15, 2013 approved XOFIGO® Injection for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. XOFIGO® is an alpha-particle emitting radiotherapeutic drug. It mimics calcium and forms complexes with hydroxyapatite at sites of increased bone turnover, as seen at metastatic lesions in the bone. XOFIGO® is a product of Bayer HealthCare Pharmaceuticals Inc.


TARCEVA® (Erlotinib)

June 4th, 2013